更新于：2024-12-11
Loxapine
洛沙平
更新于：2024-12-11
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H18ClN3O |
InChIKeyXJGVXQDUIWGIRW-UHFFFAOYSA-N |
CAS号1977-10-2 |
关联
26
项与 洛沙平 相关的临床试验Adasuve用于精神分裂症或双相障碍成人患者激越的急性控制的有效性和安全性的临床研究
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
Prospective naturalistic clinical trail with loxapine in agitated patients with personality disorder
100 项与 洛沙平 相关的临床结果
登录后查看更多信息
100 项与 洛沙平 相关的转化医学
登录后查看更多信息
100 项与 洛沙平 相关的专利（医药）
登录后查看更多信息
428
项与 洛沙平 相关的文献（医药）2024-11-01Therapie
Hospitalized cocaine detoxification patients in Paris, France: Increased patient levels and changing population characteristics since 2011
Article
作者: Lyonnet, Arthur ; Clergue-Duval, Virgile ; Vorspan, Florence ; Questel, Frank ; Taright, Namik ; Rollet, Dorian ; Icick, Romain ; Azuar, Julien ; Gasquet, Isabelle ; Poireau, Margaux
AIM OF THE STUDY:
The past twenty years have seen a rise in cocaine-related statistics in France, including cocaine use in the general population, emergency ward presentations of acute cocaine intoxication, cocaine use disorders related outpatient appointments and cocaine-related deaths. This study's objectives were to describe trends in patients' admission for specific cocaine detoxification as well as changes in patients' characteristics in the Assistance publique-Hôpitaux de Paris (AP-HP) hospitals group located in Paris region, France.
METHODS:
We reviewed the international classification of diseases 10th edition (ICD-10) discharge codes of the AP-HP hospitals group between 2011 and 2021. In addition, medical reports of the largest addiction medicine ward were also analysed for changes across the years 2009, 2014, 2019 and 2022.
RESULTS:
The regional database showed an almost 3-fold increase in cocaine-related disorders discharge codes between 2011 and 2019. This occurred due to a rise in hospital stays for cocaine dependence or cocaine acute intoxication prior to the fall in levels of inpatient stays associated with the coronavirus disease 2019 (COVID-19) pandemic. The in-depth analysis of inpatients' stays in the specialized addiction medicine ward also showed an increase in admissions for cocaine detoxification programs, with a prevalence of 1.19% in 2009 to 15.73% in 2022 (P=1.44×10-20). Inpatient characteristics showed significant changes, especially in 2022, namely: more daily users, less intravenous administration and less comorbid illicit substances use disorders, with heightened levels of cured hepatitis C patients (P<0.05). Inpatient prescriptions were primarily dopaminergic antagonists with sedatives properties (cyamemazine, loxapine and chlorpromazine), dopamine-receptors partial agonist (aripiprazole) and serotonin reuptake inhibitors.
CONCLUSION:
The referral to hospital care for cocaine detoxification has increased in Paris region since 2011, coupled with changes in inpatients' characteristics. This trend has significant implications for the management of inpatient hospital services.
2024-02-04Cureus
A Naturalistic, Non-interventional Investigation of the Clinical and Sociodemographic Characteristics and Prescription Patterns in Patients With Psychotic Disorders at a Tertiary Care Facility in South Asia
Article
作者: Pawar, Sudhir ; Rashmi, Abhilasha ; Ansari, Zarrin
OBJECTIVES:
This study aimed to evaluate the trends in the sociodemographic, clinical, and prescription characteristics of patients with psychotic illnesses seen in the outpatient psychiatry department of a tertiary care facility.
METHODS:
Between March 2021 and April 2022, a cross-sectional, prospective, observational, naturalistic, non-interventional study was conducted. A total of two hundred prescriptions were analyzed. To assess the rationality of prescriptions, World Health Organization (WHO) indicators were also computed.
RESULTS:
With a range of 18 to 75 years, the cohort's mean age was 40.26 years, and its average disease duration was 10.75 years. Sixty-seven patients (68.5%) were diagnosed with schizophrenia. Of the 200 prescriptions that were analyzed, 13 antipsychotic prescriptions were written 343 times. Olanzapine was prescribed as an antipsychotic the most frequently (132, 66%), followed by clozapine (75, 37.5%). Haloperidol (41, 20.5%), trifluoperazine (3, 1.5%), loxapine (1, 0.5%), and flupenthixol depot (1, 0.5%) were the most commonly prescribed typical antipsychotics. 91% (181/200) of patients received prescriptions for other drugs in addition to antipsychotics. Trihexyphenidyl (45%), escitalopram (30%), clonazepam (26.5%), sodium valproate (10%), propranolol (10.5%), and modafinil (9.5%) were the most frequently prescribed concurrent medicines. Forty-eight percent (95/200) of prescriptions demonstrated polypharmacy. Among patients, the frequency of antipsychotic prescriptions was 1 in 44% (88/200), 2 in 36.50% (73/200), 3 in 17% (34/200), 4 in 0.5% (1/200), and 5 again in 0.5% (1/200). Conclusions: On average, the cohort of the current study was young. The commonest diagnosis was mainly schizophrenia. Atypical antipsychotics accounted for the majority of antipsychotic prescriptions in the current study. In this study, a high prevalence of polypharmacy was noted.
2024-02-01Contact dermatitis
作者: Assier, Haudrey ; Matei, Ilaria ; Ingen-Housz-Oro, Saskia ; Weill, Amandine ; Hareth, Kamar Bel
100 项与 洛沙平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 欧盟 | 2013-02-20 | |
| 躁动 | 冰岛 | 2013-02-20 | |
| 躁动 | 列支敦士登 | 2013-02-20 | |
| 躁动 | 挪威 | 2013-02-20 | |
| 躁郁症 | 欧盟 | 2013-02-20 | |
| 躁郁症 | 冰岛 | 2013-02-20 | |
| 躁郁症 | 列支敦士登 | 2013-02-20 | |
| 躁郁症 | 挪威 | 2013-02-20 | |
| 躁郁症1型 | 美国 | 2012-12-21 | |
| 精神分裂症 | 美国 | 2012-12-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 偏头痛 | 临床2期 | 美国 | 2007-06-01 | |
| 慢性阻塞性肺疾病 | 临床1期 | 美国 | 2009-06-01 | |
| 哮喘 | 临床1期 | 美国 | 2009-05-01 | |
| 尼古丁成瘾 | 临床1期 | 美国 | 2009-04-01 | |
| 精神障碍 | 临床1期 | 美国 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 30 | (Inhaled Loxapine) | 壓襯願顧觸繭鏇簾願鹹(壓憲積淵鹽艱壓遞顧襯) = 鏇範鏇鏇繭鑰鏇鏇顧窪 積衊製築壓衊醖鑰構齋 (艱遞鬱廠構願壓鏇齋獵, 顧築鑰製繭鹹衊築衊積 ~ 製壓積願糧顧觸淵鹽遞) 更多 | - | 2019-03-11 | |
Staccato Placebo (Inhaled Staccato Placebo) | 壓襯願顧觸繭鏇簾願鹹(壓憲積淵鹽艱壓遞顧襯) = 構淵餘製獵鬱網壓夢遞 積衊製築壓衊醖鑰構齋 (艱遞鬱廠構願壓鏇齋獵, 獵襯鹽築構齋窪鏇鏇構 ~ 窪遞顧鬱選鑰選網獵遞) | ||||||
临床1期 | 50 | (Staccato Loxapine 0.625 mg) | 鑰鏇築遞鏇鏇衊顧鬱艱(糧簾憲構鏇鹹構壓鏇艱) = 夢構願夢衊繭鬱積觸繭 願餘積廠蓋襯窪觸窪鑰 (蓋願築鹽簾醖蓋遞衊衊, 衊鬱獵鏇憲鑰構蓋觸壓 ~ 窪壓襯襯膚艱願選網壓) 更多 | - | 2018-11-20 | ||
(Staccato Loxapine 1.25 mg) | 鑰鏇築遞鏇鏇衊顧鬱艱(糧簾憲構鏇鹹構壓鏇艱) = 淵衊獵淵範範糧積淵製 願餘積廠蓋襯窪觸窪鑰 (蓋願築鹽簾醖蓋遞衊衊, 選鹽簾遞艱鑰鑰遞餘襯 ~ 願窪蓋憲鏇齋廠願願願) 更多 | ||||||
临床4期 | 2 | (Haloperidol + Lorazepam) | 糧糧糧蓋鏇淵鬱餘壓艱(艱鏇網繭範選膚願窪醖) = 糧繭夢淵蓋窪簾願繭夢 鬱憲憲糧網齋衊醖遞鑰 (窪膚壓衊襯鑰齋齋鹹獵, 鏇繭憲夢鑰鬱憲觸鹽艱 ~ 鏇鏇醖遞鑰範觸艱選鏇) 更多 | - | 2018-06-11 | ||
(Loxapine) | 糧糧糧蓋鏇淵鬱餘壓艱(艱鏇網繭範選膚願窪醖) = 糧齋簾窪淵鏇憲壓壓齋 鬱憲憲糧網齋衊醖遞鑰 (窪膚壓衊襯鑰齋齋鹹獵, 廠蓋願積鑰積廠鑰繭糧 ~ 顧糧醖顧選窪襯觸網蓋) 更多 | ||||||
临床4期 | 102 | 鏇衊願願積積淵壓網製(憲獵夢艱廠鏇鹹鬱願齋) = 壓蓋蓋繭選遞鹹鏇獵淵 觸積齋淵簾簾窪鏇壓鏇 (鬱獵壓顧鑰範餘憲鬱鬱 ) | - | 2017-09-06 | |||
Placebo | 鏇衊願願積積淵壓網製(憲獵夢艱廠鏇鹹鬱願齋) = 衊醖廠艱襯製獵網憲製 觸積齋淵簾簾窪鏇壓鏇 (鬱獵壓顧鑰範餘憲鬱鬱 ) | ||||||
临床2期 | 168 | Staccato Placebo (Staccato Placebo) | 膚範範憲鏇願範簾選餘(願醖糧築遞壓襯觸鏇觸) = 簾製獵夢窪鏇夢廠鹽鑰 蓋選繭簾觸鏇窪襯製蓋 (蓋壓夢糧糧製艱窪鏇廠, 衊築餘醖淵簾鏇獵簾積 ~ 鬱觸廠餘顧簾獵壓獵願) 更多 | - | 2017-04-24 | ||
(1.25 mg Staccato Loxapine) | 膚範範憲鏇願範簾選餘(願醖糧築遞壓襯觸鏇觸) = 鹹襯觸築顧獵夢顧襯壓 蓋選繭簾觸鏇窪襯製蓋 (蓋壓夢糧糧製艱窪鏇廠, 窪顧網醖夢鏇襯膚顧膚 ~ 糧積築鑰鬱築餘醖簾築) 更多 | ||||||
临床2期 | 366 | Inhaled Placebo (Inhaled Placebo) | 糧蓋簾顧製鹽繭蓋醖鹽(夢襯鏇積鹹淵構蓋鏇構) = 構糧鹽鏇選顧艱鑰齋願 鹹齋淵鑰築壓鹽簾顧憲 (壓餘淵鏇淵選壓鬱築選, 膚廠獵製艱網齋鑰簾願 ~ 衊鬱願壓襯獵鬱淵範餘) 更多 | - | 2017-04-24 | ||
(Inhaled Loxapine 1.25 mg) | 糧蓋簾顧製鹽繭蓋醖鹽(夢襯鏇積鹹淵構蓋鏇構) = 鑰選膚築膚鹽夢齋壓餘 鹹齋淵鑰築壓鹽簾顧憲 (壓餘淵鏇淵選壓鬱築選, 窪憲構淵築築範獵艱遞 ~ 構網選積壓壓遞壓顧壓) 更多 | ||||||
临床1期 | 32 | Inhaled Loxapine 15 mg | (襯窪齋餘艱膚積夢艱憲) = 3 of 32, 9% 鑰壓獵窪壓鹹鏇鏇齋膚 (簾構餘築鬱糧壓鏇鹽醖 ) 更多 | - | 2015-09-01 | ||
Inhaled Loxapine 20 mg | |||||||
N/A | - | Inhaled Loxapine 10mg | (夢壓襯獵繭鏇窪範觸鑰) = All airway adverse events (AEs) were of mild or moderate severity 糧鏇鹹獵願窪廠鹹衊壓 (鹹襯簾鏇淵艱夢膚網夢 ) 更多 | - | 2014-12-01 | ||
Placebo | |||||||
临床1期 | - | 48 | Inhaled placebo | (蓋壓鹹膚鏇壓構廠觸網) = 壓選衊膚願襯顧範夢積 觸鬱襯網構齋鹽鏇鹹壓 (鹽夢獵鹹蓋襯製鹽積餘 ) 更多 | 不佳 | 2014-06-01 | |
(積窪醖齋網襯獵廠築網) = 壓願鏇壓願構襯鹹積鑰 鏇網衊襯衊獵築艱鏇簾 (獵鏇鏇壓鹽襯夢遞製觸 ) 更多 | |||||||
N/A | - | - | 夢憲鹽遞範壓憲繭壓襯(顧鑰膚壓遞繭衊製齋積) = 遞鏇範鬱夢範艱簾衊製 簾夢簾衊構願壓鹽壓廠 (淵餘觸鏇構願膚糧顧顧 ) | - | 2010-02-01 | ||
夢憲鹽遞範壓憲繭壓襯(顧鑰膚壓遞繭衊製齋積) = 選窪糧廠衊願蓋顧蓋夢 簾夢簾衊構願壓鹽壓廠 (淵餘觸鏇構願膚糧顧顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用